353 related articles for article (PubMed ID: 35384181)
1. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
2. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma.
Aguiar JP; Cardoso Borges F; Murteira R; Ramos C; Gouveia E; Passos MJ; Miranda A; da Costa FA
Int J Clin Pharm; 2018 Aug; 40(4):852-861. PubMed ID: 29860707
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
4. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
5. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
7. Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications.
Mandel VD; Medri M; Manganoni AM; Pavoni L; De Rosa F; Ribero S; Foca F; Andreis D; Mazzoni L; Magi S; Farnetani F; Palla M; Ulivi P; Stanganelli I
J Dermatolog Treat; 2022 May; 33(3):1368-1375. PubMed ID: 32875931
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
9. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis.
Kraehenbuehl L; Schneider S; Pawlik L; Mangana J; Cheng P; Dummer R; Meier-Schiesser B
Pharmaceuticals (Basel); 2023 Jun; 16(7):. PubMed ID: 37513847
[TBL] [Abstract][Full Text] [Related]
11. Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma.
Bateni SB; Nguyen P; Eskander A; Seung SJ; Mittmann N; Jalink M; Gupta A; Chan KKW; Look Hong NJ; Hanna TP
JAMA Dermatol; 2023 Nov; 159(11):1195-1204. PubMed ID: 37672282
[TBL] [Abstract][Full Text] [Related]
12. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
14. Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.
Perier-Muzet M; Gatt E; Péron J; Falandry C; Amini-Adlé M; Thomas L; Dalle S; Boespflug A
JAMA Dermatol; 2018 Jan; 154(1):82-87. PubMed ID: 29214290
[TBL] [Abstract][Full Text] [Related]
15. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
16. Sarcoid-like reactions in patients receiving modern melanoma treatment.
Dimitriou F; Frauchiger AL; Urosevic-Maiwald M; Naegeli MC; Goldinger SM; Barysch M; Franzen D; Kamarachev J; Braun R; Dummer R; Mangana J
Melanoma Res; 2018 Jun; 28(3):230-236. PubMed ID: 29485531
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant immunotherapy: the sting in the tail.
Higham CE; Chatzimavridou-Grigoriadou V; Fitzgerald CT; Trainer PJ; Eggermont AMM; Lorigan P
Eur J Cancer; 2020 Jun; 132():207-210. PubMed ID: 32388064
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients.
Bottlaender L; Amini-Adle M; Maucort-Boulch D; Robinson P; Thomas L; Dalle S
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):2096-2105. PubMed ID: 32078191
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous immune-related adverse events and photodamaged skin in patients with metastatic melanoma: could nicotinamide be useful?
De Giorgi V; Colombo J; Trane L; Silvestri F; Venturi F; Zuccaro B; Doni L; Stanganelli I; Covarelli P
Clin Exp Dermatol; 2022 Aug; 47(8):1558-1560. PubMed ID: 35396736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
